The other issue that’s important to remember, and that’s relevant to future trials, is that maybe the meta-analysis doesn’t work. There may be a meta-analysis that suggests benefit because in a large multi-center trial you have a very non-homogenous population. A disease like preeclampsia, as we’ve researched into that, may come about for lots of different reasons, and when you mix lots of different people together you don’t see it anymore, and only certain subsets will benefit. Now that’s only of the explanations. The explanations on the previous slide are every bit as valid but it’s something to keep stuck in your mind in this setting, and probably in other settings of poorly designed diseases too.